Blood Glucose Evaluation & Monitoring (BGEM®)
.png)
BGEM® is the world’s first non-invasive blood glucose monitoring solution powered by an AI-driven algorithm. It is a cloud-based technology that enables wearables and hearables with Photoplethysmography (PPG) sensors to assess the risk of impaired glucose regulation.​
The Global Challenge of Diabetes¹
Diabetes is a global challenge as it is rising at an alarming rate around the world. It is one of the main causes of death in most developed countries, and is also the leading cause of blindness, stroke, amputation and kidney failure.
1 in 2
Adults
(>240 million people) in the world is undiagnosed
643
Mil
people will be diabetic by 2030
537
Mil
adults worldwide lived with diabetes in 2021
Diabetes incurred US$966 billion in global health expenditure in 2021
Why the need for BGEM® ?
Regular monitoring of blood glucose plays an important part in managing diabetes risks. Health screenings or finger pricking with lancet are the common procedures used in determining blood glucose levels. Nonetheless, these are not regular and proactive routines that are built into a person’s daily life habits.
Actxa identifies the need for an innovative solution that offers frequent assessments and early detection to prevent the onset of Type 2 diabetes mellitus (T2DM) or to delay the progression of this killer illness.
What are the benefits?
Non-invasive
Scalability
Easy & convenient
Frequent Measurement
Cost-effective
Sensor Agnostic
How does it work?
Cutting-edge technology
Leveraging the latest technological advancement in signal processing, wearable technologies, and AI to assess the risk of impaired glucose regulation.
Photoplethysmography sensor
Using signals from consumer-grade wrist-worn photoplethysmography (PPG) sensors, the AI model computes the relevant digital biomarkers correlated with prediabetes or T2DM in order to monitor and evaluate diabetic risks.
Smart Watches & Fitness Wearables (Hearable too)
AI Model
Diabetic Risk
Level
What are the achievements?
01
First company in the world to develop a comprehensive AI solution that leverages consumer-grade wearables to detect blood glucose dysregulation.
02
BGEM® completed the clinical validation in 2022 with a research paper published in October 2023.
03
Won the SBR Technology Excellence Awards 2022 under the AI - Healthcare Technology Category.
04
Partnership with Joint Chinese Limited, a leading manufacturer and solution provider for digital health wearables in China, to market and distribute wearables powered by BGEM® worldwide.
05
Established a strategic collaboration with Umeox, a leader in wearables manufacturing and solutions, to integrate BGEM® into Umeox’s upcoming product lineup.
References:
1. International Diabetes Federation. (2021). IDF Diabetes Atlas.
https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf
